Glutathione

Glutathione is the body's primary endogenous antioxidant, and people run it mostly for skin health and appearance, with steady followings for detoxification, liver support, and neurological benefit. Community dosing centers on about 2.5 milligrams daily across a wide reported range, while clinician protocols run far higher, around 200 milligrams twice daily by mouth. Sleep and dream changes occasionally surface in user reports, but no other consistent side-effect pattern has emerged. The honest caveat: outside a couple of narrow tested settings, the off-label evidence base is thinner than the discourse suggests, spread across many indications each backed by only one or two small trials, often without posted results.

Half-life~14 min

Data last updated July 30, 2026

Source data

Every row behind the score.

68 total

RCTNCT001273092005 · n=100 · Piyavate Hospital

Alcohol Drinking

result Completed; results not posted

RCTNCT002270582005 · n=100 · University of Mississippi Medical Center

Seasonal Allergic Rhinitis

tested Improvement in nasal symptom scores from baseline after intervention

result Completed; results not posted

RCTNCT00266331Phase 2 · 2004 · n=150 · Nathalie Johnson

Breast Cancer

tested Reduction in skin damage

result Completed; results not posted

RCTNCT00506688Phase 2 · 2007 · n=153 · Mukoviszidose Institut gGmbH

Cystic Fibrosis

tested Differences between inhaled glutathione and inhaled normal saline with respect to the area under the curve of FEV1 % predicted (forced expiratory volume in 1 second) within the period from baseline to week 24 (V5, EOT)

result Completed; results not posted

RCTNCT01016080Phase 1 · 2009 · n=60 · Chulalongkorn University

Skin Whitening

tested Skin melanin index

result Completed; results not posted

RCTNCT010442772010 · n=61 · Milton S. Hershey Medical Center

Healthy Adults

tested Evaluation of the effect of glutathione on key biomarkers

result Completed; results not posted

RCTNCT011420242010 · n=1000 · Huashan Hospital

Nephropathy

tested Serum creatinine

result Completed; results not posted

RCTNCT01177319Phase 2 · 2003 · n=20 · University of South Florida

Parkinson's Disease

tested Timed walking test

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01398748Phase 1 · 2012 · n=34 · Bastyr University

Parkinson's Disease (PD)

tested Determination of Safety

result Completed; results not posted

RCTNCT02424708Phase 2 · 2015 · n=45 · Bastyr University

Parkinson's Disease

tested Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score

result Completed; results not posted

RCTNCT02848417Phase 1 · 2016 · n=75 · South Florida Veterans Affairs Foundation for Research and Education

Gulf War Syndrome

tested Biomarker response to therapy using a VO2 exercise test

result In progress (unknown)

RCTNCT03020719Phase 2 · 2017 · n=60 · University of Minnesota

Cystic Fibrosis

tested Change in Weight-for-age Z-score

result −0.1 Z-score (Change in Weight-for-age Z-score)

RCTNCT048164872021 · n=60 · Cairo University

Discoloration, Tooth

tested Colour assessment

result In progress (unknown)

RCTNCT05371288Early Phase 1 · 2025 · University of California, Irvine

COVID-19

tested Assess Changes in Symptoms of Post-Acute Sequelae of COVID (PASC)

result Withdrawn before enrolment

Withdrawn: No longer studying long COVID

RCTNCT069226692025 · n=232 · General Hospital of Shenyang Military Region

Drug Induced Liver Injury

tested Improvement of DILI on the second week

result In progress (recruiting)

RCTNCT07572890Phase 1 · 2026 · n=100 · Adia Med of Winter Park LLC

Chronic Kidney Disease

tested Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)

result In progress (recruiting)

RCTPMID 25633497n=44

Treatment studies

tested weight-for-age z score, BMI z score, height z score, fecal calprotectin, liver function, systemic inflammation

result GSH gained +0.67 SD wfaszs (19.1 percentile pts) vs +0.1 SD (2.1 pts) placebo; BMI +0.69 SD vs +0.22 SD; height +0.2 SD vs -0.06 SD; fecal calprotectin -52.0 vs +0.5; all P<0.0001

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

RCTPMID 33834608n=124

Treatment studies

tested skin lightening (spectrophotometry) and facial dark spot size/color at 6 and 12 weeks

result Significant skin lightening and reduction in facial dark spot size after 12 weeks with L-Cystine 500 mg + L-Glutathione 250 mg combo; superior to placebo, L-Cystine alone, and GSH alone.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

RCTPMID 36432436n=68

Treatment studies

tested Ultrasound liver steatosis grade, Hepatic Steatosis Index (HSI)

result Nutraceutical group (Vit E + L-glutathione + silymarin) showed greater NAFLD regression; HSI improved 49.3±10.1 → 43.3±9.0 (p=0.01) vs diet alone.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

RCTPMID 39920583n=90

Treatment studies

tested liver function (ALT, AST, TBIL, ALB), fibrosis markers (HA, PC III, LN), HBV-DNA negative conversion rates, adverse reactions

result ALT: 348.96→31.11 U/L (GSH+ETV) vs 347.90→56.90 U/L (ETV alone). Fibrosis markers and HBV-DNA clearance improved; no increase in adverse reactions.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

RCTPMID 41281287n=92

Treatment studies

tested serum PCIII, IVC, TNF-a, IL-6, liver function markers, nutritional status

result Entecavir + glutathione group B achieved 97.82% effective treatment rate vs 76.08% in group A; greater reductions in TNF-a, IL-6, PCIII, IVC, ALT, AST, TBIL and improved nutritional parameters.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

RCTPMID 42332243n=68

Diagnostic & mechanistic studies

tested GSH/GSSG ratio in arterial cord blood, venous cord blood, and postnatal samples

result No significant difference in GSH/GSSG ratios: arterial cord 7.5 vs 37 (p=0.52), venous cord 8.4 vs 76 (p=0.12), postnatal 14 vs 8 (p=0.98).

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

OpenNCT00323583Phase 2 · 2006 · n=80 · Seattle Cancer Treatment and Wellness Center

Adenocarincoma of Pancreas

tested Clinical response rate (PS improvement by ECOG score, analgesic dose reduction)

result In progress (unknown)

Non-randomised; effect size cannot be separated from placebo.

OpenNCT02324426Phase 1 · 2014 · n=15 · University of Washington

Parkinson's Disease

tested The concentration of metabolites before and after (in)GSH will be compared (change in mean GSH concentration)

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenPMID 16082287n=50

Treatment studies

tested HCV-RNA levels, liver enzymes (ALT), liver histology (HAI score), quality of life (SF-36)

result 48% favorable response in ≥1 parameter; ALT normalization in 44%; viral load decrease ≥1 log in 25%; histologic improvement in 36.1%; SF-36 improved in 58%. Well tolerated, no major AEs.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

OpenPMID 20973744n=15

Treatment studies

tested platelet TBARS levels and platelet membrane fluidity (fluorescence polarization)

result TBARS decreased significantly (P=0.01); platelet membrane fluidity improved significantly (P=0.001) after 3 months antioxidant supplementation including L-glutathione 5 mg/day.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

CrosPMID 28526381n=16

Treatment studies

tested flow-mediated dilation (RHI), arterial stiffness, lipid profile, oxidative stress markers

result LDL and total cholesterol reduced vs placebo (P=0.023, P=0.04); no difference in RHI or oxidative stress overall; n=7 with abnormal baseline RHI showed reduced arterial stiffness (P=0.007, P=0.037).

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

HumaPMID 36027984

Diagnostic & mechanistic studies

tested pungency intensity of allyl isothiocyanate (AITC) and piperine via sensory evaluation

result GSH and γ-Glu-Val-Gly significantly increased AITC pungency; γ-Glu-Val-Gly also increased piperine pungency. GSH effect suppressed by CaSR inhibitor NPS-2143; anserine (no CaSR) had no effect.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

CrosPMID 36357338n=17

Treatment studies

tested serum MDA, protein carbonyl, GSH, and total antioxidant capacity (TAC)

result Amlodipine vs placebo: MDA Hedges's g -0.59 (8.3% change difference), TAC g 0.42 (12.9%), GSH g 0.26 (3.1%), protein CO g -0.11 (2.2%); MDA and TAC met 5% clinical significance threshold.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

OpenPMID 37704942

Treatment studies

tested sperm DNA fragmentation index, concentration, total count, vitality

result DFI decreased 45.6%→34.8%; concentration 29.7→35.7×10⁶/mL; total count improved (p=0.012); vitality 75.5→81.1% (p<0.001)

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 38041595n=170

Diagnostic & mechanistic studies

tested Association of ROS, GSH, and D-dimer levels at admission with mortality

result Non-survivors had high D-dimer and ROS; overall mortality 43% (30.6% moderate, 69.4% severe). Elevated ROS+D-dimer predicted poor outcomes; GSH direction not explicitly quantified.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 39260810

Diagnostic & mechanistic studies

tested Intracellular GSH/GSSG ratio and extracellular native thiol/disulphide balance in blood

result AD patients had lower GSH (p<0.001) and higher GSSG/GSH vs controls; GSSG/GSH predicted severity (OR 1.352 moderate, 1.829 severe); MMSE correlated rho=-0.488 with GSSG/GSH.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 39392127n=1372

Treatment studies

tested incidence of acute kidney injury (AKI) per KDIGO/creatinine criteria

result AKI incidence 10.6% (GSH group) vs 18.0% (non-GSH group), p=0.009; multivariate OR=0.573 (95% CI 0.353–0.931, p=0.025) for GSH as independent protective factor.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

StudPMID 39436083n=26

Treatment studies

tested serum TNF-α, hs-CRP, and neutrophil-lymphocyte ratio (NLR)

result TNF-α significantly decreased (Δ5.40 pg/mL, p=0.002); hs-CRP change 0.40 mg/L (p=0.656, NS); NLR difference 0.55 (p=0.055, NS).

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

OpenPMID 39445523

Treatment studies

tested brain damage markers (S-100β, BFABP), Glasgow coma scale, Pediatric Risk of Mortality III, inflammatory cytokines (IL-6, TNF-α), lipid peroxidation (SOD)

result GSH improved brain damage markers (S-100β, BFABP), increased GCS scores, reduced PRISM III scores, lowered IL-6 and TNF-α, and decreased lipid peroxidation in pediatric SAE patients.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 39949919

Diagnostic & mechanistic studies

tested GSH/GSSG ratio as diagnostic biomarker for infection type; ROC curve diagnostic accuracy

result Bacterial infections showed higher oxidative stress markers than viral; combined GSH+GSSG analysis with heatmaps and ROC curves improved diagnostic accuracy in distinguishing infection types.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 40660530n=76

Treatment studies

tested total effective rate, ALT, AST, GGT, ALB, TNF-α, IL-17, IL-10, adverse reactions

result Total effective rate 94.59% (treatment) vs 76.92% (control, P=.029); ALT/AST significantly lower in treatment group; TNF-α and IL-17 decreased, IL-10 increased (all P=.000).

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 41011215

Diagnostic & mechanistic studies

tested association between plasma reduced glutathione and neutrophil / total leukocyte counts

result Reduced glutathione levels significantly associated with neutrophil counts (p=0.009), strongest predictor among variables; clozapine dose and treatment duration also contributed.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

CrosPMID 41096076n=27

Treatment studies

tested serum alcohol AUC, serum acetaldehyde AUC, hangover symptom questionnaire

result Ready Q: serum alcohol AUC -94.92 mg·h/dL, acetaldehyde AUC -8.441 mg·h/dL vs placebo. Theracurmin alone: alcohol AUC -117.21 mg·h/dL, acetaldehyde AUC -8.161 mg·h/dL.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 41882480

Diagnostic & mechanistic studies

tested salivary glutathione and selenium levels as biomarkers of oral cancer risk

result Glutathione reduced in OSCC (5.047±0.5115 µM) vs high-risk (5.273±0.3240 µM) and low-risk controls (5.618±0.5213 µM); selenium elevated in OSCC and high-risk vs controls.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

CrosPMID 41897500n=14

Diagnostic & mechanistic studies

tested Whole-blood GSH pharmacokinetics (iAUC0-24, Cmax, Tmax), targeted glutathione-related metabolite panel, clinical safety markers (ALT, AST, ALP, creatinine)

result LMG 300mg vs STD 500mg: iAUC0-24 1287.5 vs 517.8 µg·mL·h (p=0.0064); ΔCmax 103.9 vs 42.8 µg/mL (p=0.0003); ~2.49× higher exposure; dose-normalized ~4×. Safe over 30 days at 600 mg/d.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 42074151n=132

Diagnostic & mechanistic studies

tested glutathione redox homeostasis, antioxidative capacity, nitrosative/carbonyl/oxidative stress, inflammation (IL-12 family, albumin), angiogenesis factors, apoptosis markers

result ccRCC vs. controls: elevated oxidative/electrophile stress, hypoxia, inflammatory and angiogenic factors; reduced anti-inflammatory, antioxidant, and apoptosis markers; glutathione redox altered as active adaptive mechanism.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 42277741n=77

Diagnostic & mechanistic studies

tested serum S-(PGJ₂)-glutathione level as diagnostic biomarker; AUC, sensitivity, specificity by ROC

result S-(PGJ₂)-glutathione significantly downregulated in DAs; total-cohort AUC=0.949, sensitivity=0.789, specificity=0.949; identified as independent biomarker by multivariate logistic regression.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

CrosPMID 42328630n=16

Treatment studies

tested OSDI, FACES scale, TFBUT, Schirmer test, NEI fluorescein staining, tear cytokines

result HA + GSH-C4 significantly improved OSDI (p<0.001), FACES (p=0.012), TFBUT (p<0.001), NEI-SS (p<0.001) vs HA alone; 15/16 completed; reversible cytokine elevation noted.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

AnimalPMID 14963930

Preclinical / mechanistic research

tested rat · [Effect of subtherapeutic doses of docetaxel (taxotere) on the efficacy of radiotherapy and pro-oxidant-antioxidant balance in rats with Guerin's carcinoma].

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 17306079

Preclinical / mechanistic research

tested rat · [An experimental study on hepatotoxicity of topiramate in young rats].

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 19959951

Preclinical / mechanistic research

tested rat · Aminothiol receptors for decorporation of intravenously administered (60)Co in the rat.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 26580926

Preclinical / mechanistic research

tested rat · [Antiteratogenic capacity of resveratrol in streptozotocin-induced diabetes in rats].

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 28969397

Preclinical / mechanistic research

tested rat · A randomized study to assess the efficacy of herbal product to prevent cisplatin-induced nephrotoxicity in a rat model.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 29134983

Preclinical / mechanistic research

tested rat · Anti-hyperglycaemic Effects of Rutin on Blood Glucose, Oxidative Stress Biomarkers and Lipid Peroxidation in Alloxan-induced Hyperglycaemic Wistar Rats.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 35285204

Preclinical / mechanistic research

tested rat · [Baicalin treats cerebral ischemia reperfusion-induced brain edema in rats by inhibiting TRPV4 and AQP4 of astrocytes].

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 36571222

Preclinical / mechanistic research

tested rat · [Effect of electroacupuncture of "Weizhong" (BL40) on iron metabolism disorder in rats with lumbar multifidus muscle injury].

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 37007625

Preclinical / mechanistic research

tested rat · <i>Tapinanthus dodoneifolius</i> leaf inhibits the activity of carbohydrate digesting enzymes and improves the insulin resistance induced in rats by dexamethasone.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 42254229

Preclinical / mechanistic research

tested rat · Anti-inflammatory and antioxidative stress effects of Sclerocarya birrea (Anacardiaceae) trunk bark aqueous extract on acetic acid-induced ulcerative colitis in rats.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 42455182

Preclinical / mechanistic research

tested rat · A multi-target approach using Moringa oleifera leaf extract in ameliorating PTZ-induced epilepsy-like neurobehavior in male rats: in vivo and in silico study.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 42477751

Preclinical / mechanistic research

tested mouse · AI-2 combined with Lactobacillus rhamnosus GG remodels gut microbiota structure to alleviate intestinal oxidative stress injury in a mouse necrotizing enterocolitis model.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

In vitroDOI 10.64898/2026.02.25.707882

Preclinical / mechanistic research

tested Glutathione impacts both <i>Batrachochytrium dendrobatidis</i> virulence and amphibian cellular defence in a chytridiomycosis model

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

In vitroPMID 11395604

Preclinical / mechanistic research

tested Glycine attenuates hepatocellular depression during early sepsis and reduces sepsis-induced mortality.

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

In vitroPMID 21187282

Preclinical / mechanistic research

tested Allosteric modulation of the calcium-sensing receptor by gamma-glutamyl peptides: inhibition of PTH secretion, suppression of intracellular cAMP levels, and a common mechanism of action with L-amino acids.

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

In vitroPMID 26118571

Preclinical / mechanistic research

tested Effects of rapamycin treatment on pancreatic fibrosis, cellular apoptosis and oxidative stress in experimental chronic pancreatitis model.

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

In vitroPMID 26450796

Preclinical / mechanistic research

tested Carbon-Dot-Based Nanosensors for the Detection of Intracellular Redox State.

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

In vitroPMID 29363853

Preclinical / mechanistic research

tested Disruption of the methionine cycle and reduced cellular gluthathione levels underlie potex-potyvirus synergism in Nicotiana benthamiana.

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

In vitroPMID 35781001

Preclinical / mechanistic research

tested Different cellular mechanism of imidacloprid and acetamiprid by a combined targeted lipidomics and metabolomics approach in Neuro-2a cells.

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

In vitroPMID 35896947

Preclinical / mechanistic research

tested Glutathione Pulse Therapy: Promote Spatiotemporal Delivery of Reduction-Sensitive Nanoparticles at the "Cellular Level" and Synergize PD-1 Blockade Therapy.

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

In vitroPMID 38558242

Preclinical / mechanistic research

tested Enhanced Biocompatibility by Evaluating the Cytotoxic and Genotoxic Effects of Magnetic Iron Oxide Nanoparticles and Chitosan on Hepatocellular Carcinoma Cells (HCC).

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

In vitroPMID 39707514

Preclinical / mechanistic research

tested African swine fever virus enhances viral replication by increasing intracellular reduced glutathione levels, which suppresses stress granule formation.

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

In vitroPMID 41858012

Preclinical / mechanistic research

tested Glutathione Impacts Both Batrachochytrium dendrobatidis Virulence and Amphibian Cellular Defense in a Chytridiomycosis Model.

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

In vitroPMID 42272945

Preclinical / mechanistic research

tested Evaluating the hepatotoxicity and nephrotoxicity of herbal medicine on swiss albino mice: an in-vivo, in-vitro and in-silico insights.

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

Glutathione dosing & protocol

How Glutathione is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials

Published clinical-trial protocols · n = 23

Typical dose

250 mg5 mg – 1000 mg

typical

0
mg
mg
mg
mg
mg

distribution of 7 reported doses · darker = more

Frequency: daily
Route: oral

In research trials, glutathione was given orally at 250 mg once daily, with reported doses ranging from 5 mg to 1 g daily, and one study used 65 mg/kg per day.

23 sources

Clinician practice

Doctor & published-protocol guidance

Typical dose

200 mg

typical

0
mg
mg
mg
mg
mg

single reported dose

Frequency: twice daily
Route: sublingual

The clinician tier reports a dose of 200 mg taken sublingual twice daily, with no specified cycling regimen for this tier.

Anecdotal

Community-reported real-world use · n = 2

Typical dose

50 mg

typical

0
mg
mg
mg
mg
mg

distribution of 2 reported doses · darker = more

Frequency: unspecified
Route: subQ

Users report 50 mg subQ glutathione, with one source noting twice‑daily administration and another not specifying frequency; both used subcutaneous injection.

2 sources

Dose & protocol sources

25 linked sources are available across the research, clinician, and community tiers. Each card states what that source says, with a link to it.

Research trials 23Clinician practice 0Anecdotal 2

Research trialsNCT02251041

Peak Aspartate Aminotransferase Within First 72h Post Transplant

NCT02251041 · Phase 2 ↗

Research trialsNCT02311907

Paclitaxel/Carboplatin (PC) Induced Peripheral Neuropathy as Assessed by EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer (EORTC), Quality of Life (QLQ), Chemotherapy Induced Peripheral Neuropathy 20 (CIPN20)).

NCT02311907 · Phase 3 ↗

Research trialsNCT04105504

Dose 500 mgFrequency daily

Change from Baseline Spot UV at 4 weeks

NCT04105504 · Phase 1 ↗

Research trialsNCT01044277

Dose 500 mgFrequency daily

Evaluation of the effect of glutathione on key biomarkers

NCT01044277 ↗

Research trialsNCT00127309

Completed; results not posted

NCT00127309 ↗

Research trialsNCT00266331

Reduction in skin damage

NCT00266331 · Phase 2 ↗

1-6 of 25

Glutathione

Research Evidence

Endpoint-classified outcomes.

What has been tested in people.

Animal and in-vitro context.

Papers behind this peptide.

Every row behind the score.

Anecdotal efficacy

Antioxidant / Detoxification

Glutathione side effects

Side effect source data

Price

Glutathione dosing & protocol

Dose & protocol sources

Related peptides